Cabazitaxel and Zykadia
Determining the interaction of Cabazitaxel and Zykadia and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. However, no formal drug interaction studies have been conducted. MANAGEMENT: Concomitant use of cabazitaxel with potent CYP450 3A4 inhibitors should generally be avoided. References "Product Information. Jevtana (cabazitaxel)." sanofi-aventis , Bridgewater, NJ.
Professional:GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. However, no formal drug interaction studies have been conducted.
MANAGEMENT: Concomitant use of cabazitaxel with potent CYP450 3A4 inhibitors should generally be avoided.
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis , Bridgewater, NJ.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.